دورية أكاديمية
أعرض في EDS

MCM2, MCM4, and MCM6 in Breast Cancer: Clinical Utility in Diagnosis and Prognosis.

التفاصيل البيبلوغرافية
العنوان: MCM2, MCM4, and MCM6 in Breast Cancer: Clinical Utility in Diagnosis and Prognosis.
المؤلفون: Issac MSM; Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, Quebec, Canada H3T 1J4., Yousef E; Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, Quebec, Canada H3T 1J4., Tahir MR; The University of Montreal Hospital Research Centre, Montréal, Quebec, Canada H2X 0A9., Gaboury LA; Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, Quebec, Canada H3T 1J4; Department of Pathology and Cell Biology, Faculty of Medicine, Université de Montréal, Montréal, Quebec, Canada H3T 1J4. Electronic address: louis.gaboury@umontreal.ca.
المصدر: Neoplasia (New York, N.Y.) [Neoplasia] 2019 Oct; Vol. 21 (10), pp. 1015-1035. Date of Electronic Publication: 2019 Aug 30.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 100886622 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5586 (Electronic) Linking ISSN: 14765586 NLM ISO Abbreviation: Neoplasia Subsets: MEDLINE
أسماء مطبوعة: Publication: 2014- : [Amsterdam] : Elsevier
Original Publication: New York, NY : Stockton Press, c1999-
مواضيع طبية MeSH: Biomarkers, Tumor*, Breast Neoplasms/*diagnosis , Breast Neoplasms/*metabolism , Minichromosome Maintenance Complex Component 2/*metabolism , Minichromosome Maintenance Complex Component 4/*metabolism, Breast Neoplasms/genetics ; Breast Neoplasms/mortality ; Computational Biology/methods ; Disease Progression ; Female ; Gene Expression ; Gene Expression Profiling ; Humans ; Immunohistochemistry ; Kaplan-Meier Estimate ; Ki-67 Antigen/genetics ; Ki-67 Antigen/metabolism ; Minichromosome Maintenance Complex Component 2/genetics ; Minichromosome Maintenance Complex Component 4/genetics ; Neoplasm Grading ; Neoplasm Staging ; Prognosis ; Survival Analysis
مستخلص: Breast cancer is a heterogeneous disease comprising the estrogen receptor (ER)-positive luminal subtype which is subdivided into luminal A and luminal B and ER-negative breast cancer which includes the triple-negative subtype. This study has four aims: 1) to examine whether Minichromosome Maintenance (MCM)2, MCM4, and MCM6 can be used as markers to differentiate between luminal A and luminal B subtypes; 2) to study whether MCM2, MCM4, and MCM6 are highly expressed in triple-negative breast cancer, as there is an urgent need to search for surrogate markers in this aggressive subtype, for drug development purposes; 3) to compare the prognostic values of these markers in predicting relapse-free survival; and 4) to compare the three approaches used for scoring the protein expression of these markers by immunohistochemistry (IHC). MCM2, MCM4, MCM6, and MKI67 mRNA expression was first studied using in silico analysis of available breast cancer datasets. We next used IHC to evaluate their protein expression on tissue microarrays using three scoring methods. MCM2, MCM4, and MCM6 can help in distinction between luminal A and luminal B whose therapeutic management and clinical outcomes are different. MCM2, MCM4, MCM6, and Ki-67 are highly expressed in breast cancer of high histological grades that comprise clinically aggressive tumors such as luminal B, HER2-positive, and triple-negative subtypes. Low transcript expression of these markers is associated with increased probability of relapse-free survival. A positive relationship exists among the three scoring methods of each of the four markers. An independent validation cohort is needed to confirm their clinical utility.
(Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.)
References: Mol Cell. 2001 Nov;8(5):1093-104. (PMID: 11741544)
Eur J Biochem. 2003 Mar;270(6):1089-101. (PMID: 12631269)
Ann Oncol. 2012 Sep;23 Suppl 10:x207-10. (PMID: 22987963)
Br J Cancer. 2005 Nov 28;93(11):1295-300. (PMID: 16278669)
Cytometry. 1991;12(1):42-9. (PMID: 1999122)
Microbiol Mol Biol Rev. 2004 Mar;68(1):109-31. (PMID: 15007098)
Arch Iran Med. 2008 Sep;11(5):532-8. (PMID: 18759521)
J Cell Sci. 2001 Jun;114(Pt 11):2027-41. (PMID: 11493639)
Breast Cancer Res. 2006;8(6):216. (PMID: 17164010)
Ann Oncol. 2011 Mar;22(3):500-2. (PMID: 21343384)
Lung Cancer. 2015 Aug;89(2):189-96. (PMID: 26013954)
Breast Cancer Res Treat. 2012 Feb;131(3):765-75. (PMID: 21452023)
Nucleic Acids Res. 2017 Jul 27;45(13):e122. (PMID: 28472340)
Semin Cancer Biol. 2011 Feb;21(1):4-9. (PMID: 20851183)
Am J Cancer Res. 2014 Dec 15;5(1):52-71. (PMID: 25628920)
Cancer. 2002 Apr 15;94(8):2151-9. (PMID: 12001111)
Breast Care (Basel). 2013 Jun;8(3):221-9. (PMID: 24415975)
Nat Genet. 2007 Jan;39(1):93-8. (PMID: 17143284)
Lancet Oncol. 2011 Mar;12(3):245-55. (PMID: 21310658)
BMC Cancer. 2015 Jul 25;15:546. (PMID: 26205655)
Nat Med. 1998 Jul;4(7):844-7. (PMID: 9662379)
Br J Cancer. 2005 Oct 17;93(8):939-45. (PMID: 16189522)
Ann Oncol. 2013 Sep;24(9):2206-23. (PMID: 23917950)
Nucleic Acids Res. 2015 Jan;43(Database issue):D670-81. (PMID: 25428374)
Endocrinology. 2009 Jul;150(7):3318-26. (PMID: 19342456)
J Clin Oncol. 2015 Jul 10;33(20):2270-8. (PMID: 26033813)
Nature. 2012 Oct 4;490(7418):61-70. (PMID: 23000897)
Folia Histochem Cytobiol. 2010 Sep 30;48(3):442-6. (PMID: 21097442)
Lancet Oncol. 2010 May;11(5):414-5. (PMID: 20434714)
Nature. 2000 Aug 17;406(6797):747-52. (PMID: 10963602)
Am J Surg Pathol. 2012 Feb;36(2):283-91. (PMID: 22020044)
J Natl Cancer Inst. 2009 May 20;101(10):736-50. (PMID: 19436038)
Clin Cancer Res. 2013 Nov 15;19(22):6261-71. (PMID: 24048333)
PLoS One. 2013 Jul 17;8(7):e69607. (PMID: 23874974)
Breast Care (Basel). 2011;6(2):136-141. (PMID: 21633630)
Breast Cancer Res Treat. 2010 Oct;123(3):725-31. (PMID: 20020197)
Diagn Pathol. 2012 Jun 20;7:42. (PMID: 22515559)
Adv Anat Pathol. 2012 Jan;19(1):39-53. (PMID: 22156833)
Br J Cancer. 2012 May 22;106(11):1798-806. (PMID: 22538974)
J Clin Oncol. 2013 Jan 10;31(2):203-9. (PMID: 23233704)
Eur J Cancer. 2013 May;49(8):2000-9. (PMID: 23498875)
Mod Pathol. 2017 May;30(5):682-697. (PMID: 28084344)
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74. (PMID: 11553815)
Oncogene. 1999 Apr 8;18(14):2299-309. (PMID: 10327050)
J Clin Diagn Res. 2015 Mar;9(3):EC01-5. (PMID: 25954622)
Breast J. 2013 Jan-Feb;19(1):22-30. (PMID: 23240985)
Lancet Oncol. 2010 Feb;11(2):174-83. (PMID: 20152769)
Breast Cancer Res Treat. 2013 Jun;139(2):539-52. (PMID: 23674192)
Mod Pathol. 2013 May;26(5):658-64. (PMID: 23503643)
Nat Rev Cancer. 2006 Feb;6(2):99-106. (PMID: 16491069)
J Cell Physiol. 2000 Mar;182(3):311-22. (PMID: 10653597)
CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593)
Gut. 2002 Mar;50(3):290-1. (PMID: 11839701)
J Clin Oncol. 2003 Dec 1;21(23):4306-13. (PMID: 14645419)
Diagn Pathol. 2016 Jul 11;11(1):63. (PMID: 27401406)
Clin Cancer Res. 2006 Aug 15;12(16):4790-3. (PMID: 16914563)
Diagn Pathol. 2012 Mar 16;7:27. (PMID: 22424533)
J Clin Pathol. 2004 Jul;57(7):675-81. (PMID: 15220356)
Breast Cancer Res Treat. 2011 Jun;127(3):591-9. (PMID: 20623333)
BMC Cancer. 2008 Feb 06;8:42. (PMID: 18254960)
المشرفين على المادة: 0 (Biomarkers, Tumor)
0 (Ki-67 Antigen)
0 (MKI67 protein, human)
EC 3.6.4.12 (MCM2 protein, human)
EC 3.6.4.12 (MCM4 protein, human)
EC 3.6.4.12 (Minichromosome Maintenance Complex Component 2)
EC 3.6.4.12 (Minichromosome Maintenance Complex Component 4)
تواريخ الأحداث: Date Created: 20190903 Date Completed: 20200421 Latest Revision: 20200421
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC6726925
DOI: 10.1016/j.neo.2019.07.011
PMID: 31476594
قاعدة البيانات: MEDLINE
الوصف
تدمد:1476-5586
DOI:10.1016/j.neo.2019.07.011